More importantly, this gap was more obvious in patients undergoing chemotherapy (Figure 1b), suggesting a potential role for FASN in mediating resistance to chemotherapeutic agents in DLBCL. The gene discussed is FASN; the disease is diffuse large B-cell lymphoma.